Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $17.00 target price on the biopharmaceutical company’s stock.
Palatin Technologies Stock Up 0.8 %
PTN stock traded up $0.01 during midday trading on Thursday, reaching $1.27. The company had a trading volume of 154,073 shares, compared to its average volume of 354,457. Palatin Technologies has a 1 year low of $0.68 and a 1 year high of $5.65. The company has a market cap of $24.83 million, a price-to-earnings ratio of -0.59 and a beta of 0.99.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last issued its quarterly earnings results on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. On average, research analysts anticipate that Palatin Technologies will post -2.03 EPS for the current year.
Hedge Funds Weigh In On Palatin Technologies
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Further Reading
- Five stocks we like better than Palatin Technologies
- High Flyers: 3 Natural Gas Stocks for March 2022
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- How to Invest in Blue Chip Stocks
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Technology Stocks Explained: Here’s What to Know About Tech
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.